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Abstract 
Purpose: Skeletal-related events (SREs) negatively affect the quality of life of patients with cancer. 
Vascular endothelial growth factor receptor (VEGFR)-targeted therapy is effective against bone 
metastasis in animal models, but the clinical efficacy of anti-VEGFR inhibitors against bone metastases 
remains unclear. Therefore, we aimed to investigate the efficacy of chemotherapy with bevacizumab, an 
anti-VEGF antibody, against bone metastases. 
Methods: We retrospectively reviewed consecutive patients with nonsquamous non-small cell lung cancer 
who received first-line platinum-based chemotherapy with zoledronic acid at Shizuoka Cancer Center 
between 2007 and 2011. 
Results: Of 25 patients, 13 received bevacizumab-based chemotherapy (BEV group), and 12 received 
chemotherapy without bevacizumab (non-BEV group). The overall response (54% vs. 8%, p = 0.01) and 
disease control (100% vs. 50%, p = 0.01) rates were higher in the BEV group than in the non-BEV group. 
The bone-specific response (23% vs. 0%, p = 0.038) and disease control (100% vs. 67%, p = 0.01) rates 
were also higher in the BEV group. The median time to progression (TTP) for bone metastases was 
higher in the BEV group (13.7 months vs. 4.3 months, p = 0.06), whereas that for overall disease was 
similar between the groups (5.7 months vs. 2.6 months, p = 0.17). The proportions of patients with SREs 
were 23% and 50% in the BEV and non-BEV groups, respectively (p = 0.16). 
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Conclusion: Bevacizumab might potentiate the antitumor activity of chemotherapy against systemic 
disease and bone metastases, prolonging bone-specific TTP and reducing the incidence of SRE. 
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Introduction 
The incidence of bone metastases in patients with lung cancer is approximately 30–40%, and the 
median survival time of patients with such metastases is 7 months [1]. A more recent retrospective review 
of 435 patients with non-small cell lung cancer (NSCLC) indicated an incidence of 24% for skeletal 
metastases. In this review, most instances of skeletal metastases (66%) were detected at the time of initial 
staging [2]. 
Patients with metastatic bone disease frequently experience osteoclast-mediated bone destruction, 
resulting in clinically important complications such as a fracture, the need for bone radiation or surgical 
therapy, spinal cord compression, or hypercalcemia [3-4]. These complications, collectively known as 
skeletal-related events (SREs) [5-7], lead to pain and decreased quality of life [8]. Thus, SREs have a 
negative impact on the quality of life, performance status, and functioning of patients with cancer. In a 
Japanese retrospective review of 259 patients with NSCLC [9], 30% of patients were found to have 
skeletal metastases during their clinical course, and 50% of these patients had SREs. Among 135 stage IV 
patients, 41% had skeletal metastases at the initial staging, and 45% had SREs. 
Zoledronic acid has been used in patients with bone metastases because the drug can reduce the 
incidence of SREs and delay time to the first SRE [10]. Recently, the noninferiority of denosumab to 
zoledronic acid in delaying the time to the first SRE was demonstrated [11]. However, we believe that the 
efficacy of these drugs cannot be insufficient. The efficacy of chemotherapy against bone lesions in 
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patients with lung cancer has not been reported previously. 
Bevacizumab, an anti-vascular endothelial growth factor (VEGF) agent, provides a clinical 
benefit when combined with platinum-based chemotherapy in first-line therapy against advanced 
nonsquamous (non-Sq) NSCLC [12-14]. In particular, the response rate and progression-free survival 
(PFS) compared with those of non-bevacizumab–containing chemotherapy are improved by the addition 
of bevacizumab. Antitumor activity may be induced by the effects of bevacizumab on tumor vasculature, 
interstitial pressure, and blood vessel permeability, resulting in enhanced delivery of chemotherapy agents 
to tumor cells [15]. Nagengast et al. demonstrated that bevacizumab distribution to the bone was similar 
as that to other organs in an ex vivo biodistribution model [16]. Bäuerle et al. reported that bevacizumab 
significantly inhibited osteolysis, surrounding soft tissue tumor growth, and angiogenesis in an 
experimental model of breast cancer bone metastasis as visualized on volumetric computed tomography 
(CT) and magnetic resonance imaging (MRI) [17]. Furthermore, the blocking of VEGF-VEGF receptor 
(VEGFR)-2 signaling inhibited bone metastasis in animal models of lung cancer [18]. Therefore, VEGF 
was suggested as a therapeutic target for bone metastasis [19]. Thus, we hypothesized that 
bevacizumab-containing chemotherapy could have some clinical benefit in patients with non-Sq NSCLC 
and bone metastases. We retrospectively investigated the efficacy of bevacizumab-containing 
chemotherapy and compared it to that of chemotherapy without bevacizumab in this study. 
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Patients and methods 
Patients 
We reviewed electronic medical records of consecutive patients who visited the Shizuoka 
Cancer Center between January 2007 and December 2011. In addition, electronically stored images were 
evaluated by a diagnostic radiologist. Eligible patients were pathologically diagnosed with non-Sq 
NSCLC, received platinum-based first-line chemotherapy, had bone metastases at the time of receiving 
chemotherapy, had at least 1 evaluable bone lesion according to the Revised Response Evaluation Criteria 
in Solid Tumors (RECIST) guideline (version 1.1) [20], and received zoledronic acid continuously. We 
permitted the inclusion of patients who received EGFR-tyrosine kinase inhibitors before platinum-based 
chemotherapy. We selected carboplatin plus paclitaxel and carboplatin plus pemetrexed as the 
non-bevacizumab–containing chemotherapy regimens because we used only these regimens in 
combination with bevacizumab in our institution. The patients who received bevacizumab-containing 
chemotherapy comprised the ‘‘BEV group” and those who received chemotherapy without bevacizumab 
comprised the ‘‘non-BEV group.”  
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Evaluation 
We evaluated the objective response rate, disease control rate, time to progression of overall 
disease (TTP), time to progression of bone metastases (B-TTP), overall survival (OS), and proportion of 
patients with SREs. The response to chemotherapy was accessed according to RECIST criteria (version 
1.1). At the initial staging, we performed chest and abdominal CT, brain MRI, and positron emission 
tomography (PET)-CT/bone scintigraphy. To ascertain disease progression or the relapse of overall 
disease and bone metastases, patients were evaluated by physical examination, chest radiography, and CT 
of the chest and abdomen. If bone metastases were detected at the initial staging, the patient was regularly 
followed-up with radiography and CT. If progression of bone metastases was suspected, we additionally 
performed PET-CT, MRI, or bone scintigraphy, as required. Generally, all patients were evaluated for 
lesions during and approximately 6–8 weeks after the treatment period. 
TTP was measured from the start of first-line chemotherapy to the date of an event of 
documented disease progression/recurrence or the last follow-up visit. B-TTP was measured from the 
start of first-line chemotherapy to the date of an event of documented progression of bone metastases 
and/or SRE or the last follow-up visit. Cases of TTP or B-TTP were censored under the following 
conditions: no progression or recurrence of overall disease or bone metastases and death. The incidence 
of SREs accounted for all events that occurred from the start of platinum-based chemotherapy to the date 
of first progression of overall disease or the last follow-up visit. SREs included a pathologic fracture, 
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spinal cord compression, and the need for bone radiation or surgical therapy. OS was measured from the 
start of first-line chemotherapy to the date of death or the last follow-up visit. 
 
Statistical analysis 
All categorical variables, objective response rates, and incidences of SREs were analyzed and 
compared between the BEV and non-BEV groups using the χ2 test or Fisher’s exact test, as appropriate. 
The distributions of TTP, B-TTP, and OS were estimated using the Kaplan-Meier method, and the BEV 
and non-BEV groups were compared using the log-rank test. All p values were 2-sided, and values less 
than 0.05 were considered statistically significant. All analyses were performed using JMP 9 software 
(SAS Institute, Cary, NC). This study was approved by the institutional review board of Shizuoka Cancer 
Center. 
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Results 
A total of 25 patients, 13 patients in the BEV group and 12 patients in the non-BEV group, were 
eligible for this retrospective study. Patient characteristics are shown in Table 1. In the BEV and 
non-BEV groups, the median ages of patients were 63 and 67 years, respectively. In total, 11 of 13 (85%) 
patients in the BEV group and 9 of 12 (75%) patients in the non-BEV group were men. The BEV group 
included 11 (85%) current or ever smokers, and the non-BEV group included 7 (58%) current or ever 
smokers. The numbers of patients with an Eastern Cooperative Oncology Group (ECOG) performance 
status (PS) of 0–1 were 12 in the BEV group and 11 in the non-BEV group, and 1 patient in each group 
had an ECOG PS of 2. The EGFR status was not examined in 5 patients in the non-BEV group, but no 
statistically significant difference in EGFR status was found between the 2 groups (p = 0.41). 
The administered chemotherapy regimens are shown in Table 1. In the BEV group, 6 patients 
were treated with carboplatin, paclitaxel, and bevacizumab, whereas 7 patients were treated with 
carboplatin, pemetrexed, and bevacizumab. In the non-BEV group, 11 patients received carboplatin plus 
paclitaxel, and 1 patient received carboplatin plus pemetrexed. 
The response rates for overall disease were 54% in the BEV group and 8% in the non-BEV 
group (p = 0.01; Table 2). The disease control rates for overall disease were 100% in the BEV group and 
50% in the non-BEV group (p = 0.01; Table 2). The response rates for bone metastases were 23% in the 
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BEV group and 0% in the non-BEV group (p = 0.038; Table 3). The disease control rates for bone 
metastases were 100% in the BEV group and 67% in the non-BEV group (p = 0.01; Table 3).  
The Kaplan-Meier curve for B-TTP is shown in Fig. 1. The median B-TTPs were 13.7 months in 
the BEV group and 4.3 months in the non-BEV group (p = 0.06). The Kaplan-Meier curve for TTP is 
shown in Fig. 2. The median TTPs were 5.7 months in the BEV group and 2.6 months in the non-BEV 
group (p = 0.17). Overall disease progression was observed in 12 of 13 patients in the BEV group and in 
all patients in the non-BEV group. The median OS was 6.6 months (range, 4.0–34.7 months) in the 
non-BEV group and this was not reached (range, 6.6 months–) in the BEV group (p = 0.13). In the 
present study, the median follow-up duration was 15.1 months. 
SREs occurred in 3 patients (23%) in the BEV group and in 6 patients (50%) in the non-BEV 
group (Table 4). The types of SREs were as follows: 3 instances of the need for bone radiation and 1 
instance of spinal cord compression in the BEV group and 5 instances of the need for bone radiation, 1 
bone surgery, and 1 pathologic fracture in the non-BEV group. 
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Discussion 
To the best of our knowledge, the present study is the first report to evaluate the bone-specific 
efficacy of chemotherapy in patients with bone metastases from NSCLC. In addition, it was important to 
evaluate the bevacizumab-mediated potentiation of chemotherapeutic efficacy against bone metastases. In 
the present study, in the BEV group, the response and disease control rates for bone metastases were 23% 
and 100%, respectively, and the median B-TTP was 13.7 months. 
Rosen et al. reported a Phase 3 trial of zoledronic acid [10, 21]. Among 254 patients who 
received zoledronic acid 4 mg, 124 patients (49%) had NSCLC and 207 patients (82%) received 
chemotherapy. The best bone response rate as per the original criteria was 8%, and the disease control 
rate for bone metastases was 29%. In this study, by using the RECIST guideline (version 1.1), the 
response rate for bone metastases was 0% and the disease control rate for bone metastases was 67% in the 
non-BEV group. In contrast, the response rate for bone metastases was 23% and the disease control rate 
for bone metastases was 100% in the BEV group. Although different bone lesion response criteria were 
used for the Phase 3 trial of zoledronic acid and this study, administration of bevacizumab-containing 
chemotherapy showed some potential for eliciting an effect on bone metastases. In the same Phase 3 trial, 
the median B-TTP of patients who received zoledronic acid 4 mg was 145 days, and the proportion of 
patients with at least 1 SRE over a period of 9 months was 38%. In this study, the median B-TTPs were 
130 days in the non-BEV group and 412 days in the BEV group. In terms of the proportion of patients 
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with SREs, 50% of patients in the non-BEV group and 23% of patients in the BEV group had SREs until 
the first progression of overall disease or the last follow-up visit. These results suggest that 
bevacizumab-containing chemotherapy specifically controlled bone lesions as well as systemic lesions. 
The antitumor activity of bevacizumab-containing chemotherapy is believed to be the result of 
enhanced chemotherapy delivery to tumor cells [15]. Bevacizumab distribution to bone was similar as 
that to other organs in ex vivo biodistribution analysis [16]. Inhibiting VEGF-VEGFR-2 signaling 
inhibited bone metastasis in animal models of lung cancer with bone metastasis [18]. Solares et al. 
reported a patient with lung adenocarcinoma and bone metastases in whom a complete response was 
achieved with carboplatin, paclitaxel, and bevacizumab [22]. Paule et al. reported that 2 patients with 
renal cell carcinoma (RCC) and bone metastases who were treated with the anti-VEGFR inhibitor 
sunitinib experienced long-term survival and stabilization of bone metastases [23]. They concluded that 
VEGF-targeted agents such as sunitinib may be effective treatments for bone metastases. Furthermore, a 
retrospective analysis reported that sunitinib plus bisphosphonates such as zoledronic acid and 
pamidronate improved the response rate, PFS, and OS in cases of RCC with bone metastases [24]. In our 
study, the response rates for bone metastases were 23% in the BEV group and 0% in the non-BEV group. 
These results might validate the clinical efficacy of bevacizumab-containing chemotherapy against bone 
metastases. 
This study has several limitations. The sample size was small. This was a retrospective study 
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with an inherent potential for bias. The collection of clinical characteristics and treatment response data 
was retrospective, and the follow-up interval for physical examinations was indefinite. Therefore, future 
studies are warranted to investigate larger sample sizes. 
In conclusion, this study indicates that bevacizumab might potentiate the antitumor activity of 
chemotherapy against both systemic disease and bone metastases, thereby prolonging bone-specific TTP 
and reducing the incidence of SREs. 
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Figure legends 
 
Fig 1. 
Kaplan–Meier plot of time to progression of bone metastases (B-TTP) of patients who received 
chemotherapy containing bevacizumab (BEV group) or lacking bevacizumab (non-BEV group). The 
median B-TTPs were 13.7 months in the BEV group and 4.3 months in the non-BEV group (p = 0.06). 
 
Fig 2. 
Kaplan–Meier plot of time to progression of overall disease (TTP) of patients who received 
chemotherapy containing bevacizumab (BEV group) or lacking bevacizumab (non-BEV group). The 
median TTPs were 5.7 months in the BEV group and 2.6 months in the non-BEV group (p = 0.17). 
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BEV non-BEV P value 
Number 13 12 - 
Age median (range) 63 (35–75) 67 (40–76) 0.3255 
Sex M/F 11/2 9/3 0.5476 
Smoking Yes/No 11/2 7/5 0.1394 
PS 0/1/2 3/9/1 0/11/1 0.9530 
EGFR Mt/Wt/unknown 4/9/0 2/5/5 0.4054 
Regimen of 
chemotherapy 
CBDCA+PTX 
CBDCA+PEM 
CBDCA+PTX+BEV 
CBDCA+PEM+BEV 
- 
- 
6 
7 
11 
1 
- 
- 
- 
Mt, mutation; Wt, wild type; CBDCA, carboplatin; PTX, paclitaxel; PEM, pemetrexed; BEV, 
bevacizumab 
 
Table 1  Patients characteristics and chemotherapy regimens 
Best response BEV (n = 13) non-BEV (n = 12) P value 
PR 
SD 
PD 
7 
6 
0 
1 
5 
6 
Response rate 54% 8% 0.01 
Disease control rate 100% 50% 0.01 
PR, partial response; SD, stable disease; PD, progressive disease 
  
 
Table 2  Response and control rates for overall disease 
Best response BEV (n = 13) non BEV (n = 12) P value 
PR 
SD 
PD 
3 
10 
0 
0 
8 
4 
Response rate 23% 0% 0.04 
Disease control rate 100% 67% 0.01 
PR, partial response; SD, stable disease; PD, progressive disease 
  
Table 3  Response and control rates for bone metastases 
Table 4  Proportion of patients with SREs until the first documented event of disease 
progression 
BEV 
n = 13 
non BEV 
n = 12 
SREs* 
Radiation to bone 
Surgery to bone 
Spinal cord compression 
pathologic fracture 
3 (23%) 
3 
0 
1 
0 
6 (50%) 
5 
1 
0 
1 
SRE; skeletal-related events 
 *P = 0.16  
Median B-TTP 
BEV 13.7 months 
non-BEV   4.3 months 
 P = 0.06 (Log-rank test)         
Fig. 1  Time to progression of bone metastases 
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Fig. 2  Time to progression of overall disease 
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